ArticleNew microbes and new infections2026
High prevalence of anal HPV16 infection among HIV-negative men who have sex with men and transgender women using pre-exposure prophylaxis: a single-centre retrospective cross-sectional study.
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemsex and childhood trauma: evidence from a explorative matched case-control analysis.European archives of psychiatry and clinical neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anal squamous cell carcinoma is a preventable digestive malignancy driven by persistent infection with high-risk human papillomavirus (HPV), particularly HPV16. Current anal cancer screening strategies primarily target HIV-positive populations and may not reflect evolving risk profiles in HIV-negative men who have sex with men (MSM) using pre-exposure prophylaxis (PrEP). Methods: We conducted a retrospective cross-sectional study in HIV-negative MSM and transgender women (TGW) using PrEP who underwent routine proctology consultations. Anal samples were collected for cytology and high-risk HPV DNA testing, and targeted biopsies were performed when lesions were identified on standard anoscopy. We estimated the prevalence of anal HPV16 infection, identified associated behavioral and clinical factors, and assessed the prevalence of cytological and histological anal abnormalities. Results: Among 458 participants with interpretable HPV testing, anal HPV16 infection was detected in 32.5%. HPV16 positivity was independently associated with chemsex practices (OR 1.76; 95%CI1.14-2.71) and a history of rectal bacterial sexually transmitted infections since PrEP initiation (OR 1.64; 95% CI, 1.10-2.47). Cytological abnormalities were observed in 22.9% of participants and were more frequent in those with HPV16 infection (31.1% vs. 19.1%; OR 1.9; 95%CI 1.18-3.05; p = 0.008). Histological assessment was available for 92 individuals; 18.6% had low-grade lesions and 1.3% had high-grade lesions. Overall, HPV-related histological lesions were present in 19.9% of participants. Conclusions: HIV-negative MSM and TGW using PrEP exhibit a high burden of anal HPV16 infection and cytological abnormalities. These findings suggest that selected high-risk PrEP users may benefit from targeted anal cancer screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.